Cargando…

A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications

BACKGROUND: Pyridoxine is frequently used to treat capecitabine-induced hand–foot syndrome (HFS), although the evidence of benefit is lacking. We performed a randomised placebo-controlled trial to determine whether pyridoxine could avoid the need for capecitabine dose modifications and improve outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Corrie, P G, Bulusu, R, Wilson, C B, Armstrong, G, Bond, S, Hardy, R, Lao-Sirieix, S, Parashar, D, Ahmad, A, Daniel, F, Hill, M, Wilson, G, Blesing, C, Moody, A M, McAdam, K, Osborne, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419962/
https://www.ncbi.nlm.nih.gov/pubmed/22814578
http://dx.doi.org/10.1038/bjc.2012.318
Descripción
Sumario:BACKGROUND: Pyridoxine is frequently used to treat capecitabine-induced hand–foot syndrome (HFS), although the evidence of benefit is lacking. We performed a randomised placebo-controlled trial to determine whether pyridoxine could avoid the need for capecitabine dose modifications and improve outcomes. METHODS: A total of 106 patients planned for palliative single-agent capecitabine (53 in each arm, 65%/ 35% colorectal/breast cancer) were randomised to receive either concomitant pyridoxine (50 mg po) or matching placebo three times daily. RESULTS: Compared with placebo, pyridoxine use was associated with an increased rate of avoiding capecitabine dose modifications (37% vs 23%, relative risk 0.59, 95% CI 0.29, 1.20, P=0.15) and fewer grade 3/4 HFS-related adverse events (9% vs 17%, odds ratio 0.51, 95% CI 0.15–1.6, P=0.26). Use of pyridoxine did not improve response rate or progression-free survival. CONCLUSION: Pyridoxine may reduce the need for capecitabine dose modifications and the incidence of severe HFS, but does not impact on antitumour effect.